Researchers at Migal Galilee Research Institute, MIGAL, located in Israel Friday, disclosed they they have gotten a breakthrough in the development of vaccine against avian Coronavirus Infectious Bronchitis Virus, IBV, stating they are closed to creating a human vaccine against coronavirus (COVID-19).
The further disclosed that they have achieved a scientific breakthrough to the creation of a vaccine against the epidermic that have sabotage the World’s economy.
IBV is a disease affecting animals. The researchers said the vaccine against IBV has been proven in pre-clinical trials.
Following the completion of a four years multi-disciplinary research funded by Israel’s ministry of science and technology in cooperation with Israel’s ministry of agriculture, MIGAL said, it has now made required genetic adjustments to adapt the vaccine to COVID-19, the human strain of coronavirus, and is working to achieve the safety approvals that will enable in-vivo testing, enable the initiation of production of a vaccine to counter the coronavirus epidemic currently spreading throughout the world, which so far has claimed 2,666 lives.
From MIGAL research, it was discovered that the poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism, a fact that increases the likelihood of achieving an effective human vaccine in a very short period of time.
According to MIGAL’s Chief Executive Officer, David Zigdon, “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days.
“This will be an oral vaccine, making it particularly accessible to the general public. We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion final product development and regulatory activities.”
Also, MIGAL’s biotechnology group leader, Chen Katz, said: “The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis (a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material), causing the body to form antibodies against the virus. In pre-clinical (IN-VIVO) trials, MIGAL’s researchers have demonstrated that the oral vaccination induces high levels of specific anti-IBV antibodies.”